Amyotrophic Lateral Sclerosis (ALS) Investment Landscape

Investment Landscape: Amyotrophic Lateral Sclerosis

Overview

Investment Landscape: Amyotrophic Lateral Sclerosis covers the current R&D investment,
clinical trial pipeline, and funding trends for Amyotrophic Lateral Sclerosis research.

Last updated: 2026-03-22 03:00 PT

Clinical Trial Pipeline

Total Clinical Trials: 1569 Active Trials (Recruiting/Active): 434

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 138 |
| PHASE1, PHASE2 | 77 |
| PHASE2 | 216 |
| PHASE2, PHASE3 | 49 |
| PHASE3 | 71 |
| PHASE4 | 20 |
| NA | 527 |
| Not Applicable | 440 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 273 |
| ACTIVE_NOT_RECRUITING | 78 |
| NOT_YET_RECRUITING | 83 |
| COMPLETED | 747 |
| TERMINATED | 103 |
| WITHDRAWN | 39 |

Top Therapeutic Approaches

• mitochondrial: 696 trials
• genetic: 117 trials
• amyloid: 74 trials
• tau: 37 trials
• tauro: 37 trials
• neuroinflammation: 14 trials
• metal: 14 trials
• metabolic: 12 trials

Investment Context

Amyotrophic lateral sclerosis has 1,569 total clinical trials, representing a significantly smaller research investment compared to AD and PD. The limited Phase 3 count (71) reflects the challenge of conducting large-scale trials for this rapidly progressive disease. The high termination rate (103 trials) highlights the need for better therapeutic targets.

Key Investment Themes

...

Investment Landscape: Amyotrophic Lateral Sclerosis

Overview

Investment Landscape: Amyotrophic Lateral Sclerosis covers the current R&D investment,
clinical trial pipeline, and funding trends for Amyotrophic Lateral Sclerosis research.

Last updated: 2026-03-22 03:00 PT

Clinical Trial Pipeline

Total Clinical Trials: 1569 Active Trials (Recruiting/Active): 434

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 138 |
| PHASE1, PHASE2 | 77 |
| PHASE2 | 216 |
| PHASE2, PHASE3 | 49 |
| PHASE3 | 71 |
| PHASE4 | 20 |
| NA | 527 |
| Not Applicable | 440 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 273 |
| ACTIVE_NOT_RECRUITING | 78 |
| NOT_YET_RECRUITING | 83 |
| COMPLETED | 747 |
| TERMINATED | 103 |
| WITHDRAWN | 39 |

Top Therapeutic Approaches

• mitochondrial: 696 trials
• genetic: 117 trials
• amyloid: 74 trials
• tau: 37 trials
• tauro: 37 trials
• neuroinflammation: 14 trials
• metal: 14 trials
• metabolic: 12 trials

Investment Context

Amyotrophic lateral sclerosis has 1,569 total clinical trials, representing a significantly smaller research investment compared to AD and PD. The limited Phase 3 count (71) reflects the challenge of conducting large-scale trials for this rapidly progressive disease. The high termination rate (103 trials) highlights the need for better therapeutic targets.

Key Investment Themes

• Genetic Subtypes: Growing stratification based on SOD1, C9orf72, and other genetic markers
• Neuroprotection: Emphasis on preserving motor neuron function
• Repositioning: Drug repurposing from other neurological conditions
• Biomarkers: Critical need for trial enrichment biomarkers

Emerging Investment Areas

With 103 terminated trials, ALS remains one of the most challenging neurodegenerative indications. RNAi-based therapies targeting SOD1 and C9orf72 have shown promise in early trials. Astrocyte modulation represents a novel approach to restore neuronal support. Metabolic interventions targeting energy dysfunction are gaining traction as a complementary strategy.

Priority Research Gaps

Late-Stage Development Bottleneck

Only 4.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.

Recommended Priorities

Phase 2→3 Translation: Enhance predictive biomarkers and clinical endpoints

Trial Design Innovation: Adaptive trials and platform protocols

Patient Recruitment: Investment in trial-ready cohorts and registry infrastructure

Therapeutic Target Priorities

Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:

• mitochondrial: 696 trials - Well-established
• genetic: 117 trials - Well-established
• amyloid: 74 trials - Well-established
• tau: 37 trials - Growing area
• tauro: 37 trials - Growing area

Investment Outlook

Near-Term Opportunities (1-3 Years)

Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.

Medium-Term Opportunities (3-5 Years)

Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.

Long-Term Vision (5-10 Years)

Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.

Related Pages

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [C9orf72](/entities/c9orf72)
• [Clinical Trials: ALS](/clinical-trials)

See Also

• [NeuroWiki Home](/home)
• [Investment Landscape Overview](/content/investment)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/)
• [SEC Filings](https://www.sec.gov/edgar/searchedgar/companysearch)
• [Google Finance](https://www.google.com/finance)

References

ClinicalTrials.gov (n.d.)